{{Rsnum
|rsid=1154865
|Chromosome=12
|position=73596057
|Orientation=plus
|GMAF=0.2029
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 68.8 | 31.2 | 0.0
| HCB | 60.0 | 37.8 | 2.2
| JPT | 75.6 | 24.4 | 0.0
| YRI | 58.7 | 28.6 | 12.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 60.0 | 37.8 | 2.2
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{GWAS Summary
|SNP=rs1154865
|PubMedID=17903305
|Condition=Breast cancer
|Gene=Intergenic
|Risk Allele=
|pValue=7.00E-007
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs1154865
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:17903305; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A genome-wide association study of breast and prostate cancer in the NHLBI's Framingham Heart Study (Initial Sample Size: 1,345 individuals (Framingham); Replication Sample Size: NR). This variant is associated with Breast cancer.
|Drugs=
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356383
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1154865
|overall_frequency_n=26
|overall_frequency_d=128
|overall_frequency=0.203125
|n_genomes=18
|n_genomes_annotated=0
|n_haplomes=23
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}